相似文献
1
Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304.
Antimicrob Agents Chemother. 1989 Oct;33(10):1735-40. doi: 10.1128/AAC.33.10.1735.
2
Efficacy of SCH39304 in murine cryptococcosis.
Antimicrob Agents Chemother. 1989 Aug;33(8):1242-6. doi: 10.1128/AAC.33.8.1242.
3
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.
Antimicrob Agents Chemother. 1986 Apr;29(4):579-83. doi: 10.1128/AAC.29.4.579.
4
The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis.
J Antimicrob Chemother. 1990 Sep;26(3):387-97. doi: 10.1093/jac/26.3.387.
5
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Antimicrob Agents Chemother. 1996 Aug;40(8):1910-3. doi: 10.1128/AAC.40.8.1910.
6
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.
Antimicrob Agents Chemother. 1996 Oct;40(10):2243-7. doi: 10.1128/AAC.40.10.2243.
7
Discovery of New Tricyclic Oxime Sampangine Derivatives as Potent Antifungal Agents for the Treatment of Cryptococcosis and Candidiasis.
J Med Chem. 2024 Mar 28;67(6):4726-4738. doi: 10.1021/acs.jmedchem.3c02331. Epub 2024 Mar 15.
8
Fluconazole therapy for experimental cryptococcosis and candidiasis in the rabbit.
Rev Infect Dis. 1990 Mar-Apr;12 Suppl 3:S299-302. doi: 10.1093/clinids/12.supplement_3.s299.
9
Efficacies of high-dose fluconazole plus amphotericin B and high-dose fluconazole plus 5-fluorocytosine versus amphotericin B, fluconazole, and 5-fluorocytosine monotherapies in treatment of experimental endocarditis, endophthalmitis, and pyelonephritis due to Candida albicans.
Antimicrob Agents Chemother. 1999 Dec;43(12):2831-40. doi: 10.1128/AAC.43.12.2831.
10
In vitro and in vivo antifungal activities of T-2307, a novel arylamidine.
Antimicrob Agents Chemother. 2008 Apr;52(4):1318-24. doi: 10.1128/AAC.01159-07. Epub 2008 Jan 28.
引用本文的文献
1
The Rabbit Model of Cryptococcal Meningitis.
Methods Mol Biol. 2024;2775:13-27. doi: 10.1007/978-1-0716-3722-7_2.
2
Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis.
mBio. 2022 Dec 20;13(6):e0234722. doi: 10.1128/mbio.02347-22. Epub 2022 Oct 12.
3
Pathogenesis of pulmonary Cryptococcus gattii infection: a rat model.
Mycopathologia. 2010 Nov;170(5):315-30. doi: 10.1007/s11046-010-9328-z. Epub 2010 Jun 15.
4
In vitro and in vivo efficacies of the new triazole albaconazole against Cryptococcus neoformans.
Antimicrob Agents Chemother. 2004 Feb;48(2):384-7. doi: 10.1128/AAC.48.2.384-387.2004.
5
In vitro and in vivo efficacy of the triazole TAK-187 against Cryptococcus neoformans.
Antimicrob Agents Chemother. 1998 Oct;42(10):2630-2. doi: 10.1128/AAC.42.10.2630.
6
In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Antimicrob Agents Chemother. 1996 Aug;40(8):1910-3. doi: 10.1128/AAC.40.8.1910.
7
Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans.
Clin Microbiol Rev. 1995 Oct;8(4):515-48. doi: 10.1128/CMR.8.4.515.
8
The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.
Infect Immun. 1993 Oct;61(10):4446-51. doi: 10.1128/iai.61.10.4446-4451.1993.
9
Pharmacokinetics of the triazole antifungal agent genaconazole in healthy men after oral and intravenous administration.
Antimicrob Agents Chemother. 1994 Dec;38(12):2758-62. doi: 10.1128/AAC.38.12.2758.
10
Treatment of murine pulmonary blastomycosis with SCH 39304, a new triazole antifungal agent.
Antimicrob Agents Chemother. 1990 May;34(5):896-8. doi: 10.1128/AAC.34.5.896.
本文引用的文献
1
Chronic cryptococcal meningitis: a new experimental model in rabbits.
Am J Pathol. 1980 Oct;101(1):177-94.
2
Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis.
Am J Med. 1983 Jan 24;74(1B):58-63. doi: 10.1016/0002-9343(83)90515-6.
3
Treatment of paracoccidioidomycosis with ketoconazole: a three-year experience.
Am J Med. 1983 Jan 24;74(1B):48-52. doi: 10.1016/0002-9343(83)90513-2.
4
Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients.
Am J Med. 1983 Jan 24;74(1B):23-9. doi: 10.1016/0002-9343(83)90511-9.
5
Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Diseases collaborative antifungal study.
Ann Intern Med. 1983 Jan;98(1):13-20. doi: 10.7326/0003-4819-98-1-13.
6
Oral ketoconazole. An effective and safe treatment for dermatophytosis.
Arch Dermatol. 1981 Mar;117(3):129-34. doi: 10.1001/archderm.117.3.129.
7
Obfuscation of the activity of antifungal antimicrobics by culture media.
J Infect Dis. 1972 Oct;126(4):353-61. doi: 10.1093/infdis/126.4.353.
8
Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and Candida albicans endocarditis with pyelonephritis.
Antimicrob Agents Chemother. 1985 Dec;28(6):751-5. doi: 10.1128/AAC.28.6.751.
9
Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits.
Antimicrob Agents Chemother. 1986 Apr;29(4):579-83. doi: 10.1128/AAC.29.4.579.
10
Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits.
J Antimicrob Chemother. 1985 Jul;16(1):81-6. doi: 10.1093/jac/16.1.81.
Zotero 插件